Latest news with #JimJoyce
Yahoo
01-06-2025
- Entertainment
- Yahoo
Braves vs. Phillies Game 2 Highlights
Armando Galarraga back in Detroit, talks near-perfect game: 'Highlight of my career' Armando Galarraga was back in town on Saturday, signing autographs with plenty of "28 outs" inscriptions. "It's the highlight of my career. The way me and Jim Joyce handled it, we handled it really well," the former Tigers pitcher told Brad Galli at the Detroit Sports Spectacular. 1:08 Now Playing Paused Ad Playing
Style Blueprint
22-05-2025
- General
- Style Blueprint
The Best Things to Do in Henry County, GA This Memorial Day
Share with your friends! Pinterest LinkedIn Email Flipboard Reddit Central Georgia's Henry County is best known as the home of Atlanta Motor Speedway, which hosts two NASCAR race weekends every year. However, there's much more to this county just south of the Atlanta International Airport than fast cars! Memorial Day and Veterans Day are both important occasions in Henry County, so if you're interested in recognizing living veterans and those who have passed on, a visit to Henry County belongs on your bucket list. Here are some things to do in Henry County to help you plan your trip. Pin There are more than a dozen military bases in Georgia, and many veterans have chosen Henry County to retire, settling into towns like McDonough, Hampton, Stockbridge, and Locust Grove. This concentration of retired veterans engenders sincere respect for and interest in military history, and the county residents go out of their way to recognize the service of their neighbors through memorials, museums, and even a squadron of Vietnam-era helicopters that are still in service. Heritage Park in McDonough encompasses 129 acres dedicated to recognizing the brave Americans who served in the military. The park features a paved walking track, softball fields and playgrounds, pavilions, and gardens. Most importantly, Heritage Park is the site of two significant military memorials — the Veterans Wall of Honor and the Heritage Park Veterans Museum. A walkway approaching the Wall of Honor is lined with flags and benches to offer spaces for quiet contemplation. The Wall is unique in the country as the only memorial associated with Gold Star Families (representing the families of fallen soldiers) not located within a military base. Family members must request inclusion on the wall; many submit portraits of the departed to include in the display. Most honorees are Georgia veterans. Two Central Georgia recipients of the Medal of Honor are also recognized in Heritage Park. Pin Pin A large red barn on the park grounds is home to the entirely volunteer-run Heritage Park Veterans Museum. Henry County owns the building and pays the utility bills, but the museum is operated by volunteers, mostly veterans, under the leadership of former tank instructor Jim Joyce. Pin Starting in 2010 with just a handful of artifacts, the museum now curates over 20,000 items. Almost every piece in the collection was donated by a veteran or a family member who wants to keep the memory of their military service alive and share it with the public. Pin More than just a collection of displays to walk past while reading informational plaques, the Heritage Veterans Park Museum tells the real stories of those who wore the uniforms, wielded the weapons, drove the ambulances, or worked in the munitions factories. Veterans offer free tours of the collection, and you'd better let them know in advance how much time you'd like to spend, because they can tell fascinating stories all day. The staff have free rein to individualize their own tours and share personal experiences while maintaining the reverence appropriate in a memorial setting. The collection includes dozens of mannequins wearing donated uniforms representing members of different military branches and the stories of the people who wore them. Pin Pin Dioramas and models offer the opportunity to actually experience the day-to-day life of military members during war and peacetime. Pin Pin Donated weapons on display range from handguns and bayonets to large-scale ammunition. Pin Vehicles in the museum include military transports, ambulances, and one of only three gyroscope prototypes produced with the intent of dropping them to downed helicopter pilots in Vietnam so they could fly themselves out of trouble. Unfortunately, the gyros required at least 60 feet of unobstructed flat land to take off, which was too difficult to find in the jungles of the military theater. When the museum arrived to pick up the gyrocopter from its previous owners, it was running on the tarmac, and the donors asked if anyone wanted to fly it home. Considering it basically looks like an office chair strapped to a motor and a propeller, the museum intelligently decided to bring it back to McDonough on a trailer. Pin It's a short trip south from McDonough to Locust Grove in Henry County, where you can visit another military memorial. Dedicated on Memorial Day in 2024, the Locust Grove Veterans Memorial recognizes the bravery and sacrifices of members of every military branch. Pin A decommissioned World War II-era M1A1 anti-aircraft cannon stands guard over the City Hall grounds in Locust Grove, and large plaques honor the Army, Navy, Marines, Air Force, Coast Guard, and Space Force. Donors have sponsored bricks in the walkway leading to the plaques to recognize the service of loved ones. Pin For an even more active historical experience, head to Henry County Airport next to the Atlanta Motor Speedway. One of the hangars at the airport houses the headquarters of the Army Aviation Heritage Foundation and Flying Museum. A volunteer crew of pilots and mechanics maintains a fleet of three Vietnam War-era Bell UH-1H Huey helicopters and three Bell AH-1 Cobra helicopters. Volunteers offer hangar tours on Tuesdays through Saturdays, where you can learn the stories of these birds' experience in combat from veterans who piloted and rode in them. The Hueys served as transport vehicles, dropping soldiers into combat and rescuing the wounded as air ambulances. The Cobra was an attack helicopter, only three feet wide and armed to the teeth with rockets and machine guns. These days, the helicopters travel around the country, appearing at air shows, making flyovers at veterans' funerals, and offering the opportunity for veterans to share their own stories, some of which their own families have never heard before. Pin Pin To help raise funds to keep the choppers flying, the AAHF offers 'Ride Saturdays' where civilians can actually experience what it was like to travel inside the helicopters and feel the power of the engines as they take passengers through the same sorts of maneuvers that the aircraft would make in actual combat situations. Pin The Hueys can hold up to 10 passengers, and larger groups can schedule private flights in advance. The time aloft is only about 15 minutes per flight, but it feels a lot longer thanks to the exhilarating sensation of flying in an open cabin with the wind whipping through open doors. If you sit in the side doors, your toes actually stick over the edge of the railing, but don't worry, they'll strap you in safely before takeoff. Once back on solid ground, passengers can ask questions of past soldiers and pilots who actually went into combat in these powerful choppers. But most importantly, they'll go home with a better understanding of the sacrifices these brave military veterans made to protect our country. Pin ********** For more travel inspiration, subscribe to StyleBlueprint's FREE daily emails! About the Author Chris Chamberlain
Associated Press
12-03-2025
- Health
- Associated Press
Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making
NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ('Sigyn' or the 'Company') (OTCQB: SIGY) today released the following note authored by its CEO, Jim Joyce. Dear Reader, Blood purification technologies have emerged to become leading post-exposure countermeasures to treat emerging pandemic viruses. When properly designed, these devices can also serve a dual-use purpose in everyday medicine. In this regard, Sigyn TherapyTM is a candidate first-line countermeasure to address viral threats, yet it also offers a mechanism to potentially enhance and prolong the lives of the 550,00 end-stage renal disease (ESRD) patients who rely on dialysis for survival in the United States. Additionally, Sigyn Therapy(TM) is able to target circulating factors underlying sepsis, a currently untreatable condition that is a leading cause of U.S. hospital deaths. The U.S. Government has supported the development of blood purification therapies through the Defense Advanced Research Projects Agency (DARPA). If you're unfamiliar, the Economist Magazine describes DARPA as 'the agency that shaped the modern world,' having contributed to groundbreaking innovations such as GPS, drones, stealth technology, the personal computer, and even the internet. DARPA Dialysis-Like Therapeutics Program DARPA also has a long history of supporting breakthrough advances in medicine. In 2010, the agency launched a five-year program entitled Dialysis-Like Therapeutics (DLT) to advance blood purification technologies to treat bloodstream infections and sepsis. Among the recipients of a DLT program contract was Aethlon Medical. As the founder of Aethlon, I oversaw development of the Hemopurifier(TM), a broad-spectrum virus clearance device that became the first blood purification technology to receive FDA Emergency-Use Authorization (EUA) to treat an emerging pandemic virus. In this case, Ebola virus, which occurred during the DLT program and under my leadership. Subsequently, blood purification therapies developed by two other members of the DARPA DLT team would be among the first therapies to receive EUA approval from FDA to treat COVID-19. Note: As compared to the Hemopurifier(TM), we designed Sigyn Therapy(TM) with the intent to process the bloodstream more efficiently; to have a greater capacity to capture therapeutic targets; to addresses viral pathogens plus a wide range of inflammatory targets; and to improve scalability with lower production costs. mRNA Vaccine Research Initiatives Not long after the launch of its DLT program, DARPA initiated a rapid mRNA vaccine development program that would play pivotal role in the development of the Moderna COVID-19 vaccine. When COVID-19 spread across the globe five years ago, the world faced an urgent need for a vaccine. At the time, the record for the fastest development of a vaccine to address a new virus was four years. In a groundbreaking achievement, mRNA-based vaccines from Moderna and Pfizer/BioNTech were available within a year of COVID-19 being declared a global health emergency by the World Health Organization. A study published in the journal The Lancet Infectious Diseases; estimated that these vaccines prevented between 14.4 to 19.8 million deaths worldwide in just their first year of distribution. This unprecedented speed in vaccine development may have shifted the historic focus of post-exposure treatment countermeasures from single-target antiviral drugs to broad-spectrum blood purification technologies. Especially as preventative vaccines can be developed and distributed in a mere fraction of the time it takes to bring a post-exposure antiviral drug to market. Whereas blood purification therapies can be available at the outset of a viral outbreak. Potential Advantages of Sigyn Therapy As compared to a post-exposure antiviral drug, Sigyn Therapy(TM) offers several key advantages. Unlike antiviral drugs, our technology provides an expansive mechanism of action to reduce the circulating presence of viruses, toxins, inflammatory cytokines, and other deleterious factors from the bloodstream of infected individuals. While antiviral drugs can target a specific type of virus, Sigyn Therapy(TM) offers a broad-spectrum strategy to potentially address different strains, species, and families of viruses. In closing, Sigyn Therapy(TM) is a candidate first-line countermeasures to address emerging viral threats. The continued convergence of global warming, urban crowding, and international travel will fuel new outbreaks. The question is not if, but how often these outbreaks will occur, how many lives will be lost, and what will be the global economic impact as emerging viral threats will not be constrained by borders. In the meantime, the expansive mechanism of Sigyn Therapy(TM) allows for its potential dual use in everyday medicine. Our lead clinical opportunity incorporates Sigyn Therapy(TM) in series with regularly scheduled dialysis treatments to reduce endotoxemia and concurrent inflammation that contributes to shorten the lives of end-stage renal disease (ESRD) patients. Extending the lives of those suffering from ESRD could establish a strategic competitive advantage within the dialysis industry. Thank you for taking the time to read my note. Sincerely, Jim About Sigyn Therapeutics(TM) Sigyn Therapeutics is developing next-generation blood purification therapies to address life-threatening infectious disease disorders. Sigyn Therapy(TM) has been demonstrated to reduce the presence of viral pathogens, bacterial toxins, inflammatory cytokines, and other relevant therapeutic targets from human blood plasma. Based on these capabilities, Sigyn Therapy(TM) is a candidate to treat life-threatening viruses, endotoxemia, and sepsis, the leading cause of death in U.S. hospitals. The clinical protocol of first-in-human studies incorporates Sigyn Therapy into regularly scheduled dialysis treatments to address endotoxemia and concurrent inflammation, which are highly prevalent disorders that shorten the lives of end-stage renal disease (ESRD) patients. The value of extending ESRD patient lives is quantifiable based its potential impact on dialysis industry revenues. The Company also has an oncology pipeline comprised of ImmunePrep(TM), a platform to enhance the delivery of immunotherapeutic antibodies; ChemoPrep(TM) to improve the delivery of chemotherapeutic agents; and ChemoPure(TM) to reduce chemotherapy toxicity. If successfully advanced, the Company's therapies offer to provide strategic value to the dialysis and biopharmaceutical industries. Sigyn Therapeutics, Inc. Johan Louw Senior Vice President of Strategic Programs 281.660.1815 [email protected] CEO, Inventor Cautionary Note Regarding Forward-Looking Statements This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. ('Sigyn') that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as 'may,' 'believe,' 'anticipate,' 'expect,' 'intend,' 'plan,' 'project,' 'will,' 'projections,' 'estimate,' 'potentially' or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption 'Risk Factors' in the Company's Annual Report on Form 10-K, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Associated Press
25-02-2025
- Business
- Associated Press
Sigyn Therapeutics to be Featured in Fireside Chat With Zacks Healthcare Analyst
The Exclusive Event Kicks-Off Tomorrow February 26th at 4pm Eastern SAN DIEGO - February 25, 2025 ( NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ('Sigyn' or the 'Company') (OTCQB: SIGY), a developer of next-generation blood purification devices to treat cancer and life-threatening infectious disease disorders, disclosed today that Company CEO, Jim Joyce, will participate in a Fireside Chat tomorrow with Zacks Senior Healthcare Analyst, John Vandermosten. Zacks is a leading investment research firm focusing on stock research, analysis and recommendations. This exclusive event is being hosted by Force Family Office, the largest network of family offices in the United States with a substantial and growing presence internationally. The Fireside Chat will review the emergence of blood purification therapies to address life-threatening infectious disease conditions that are beyond the reach of drugs and additionally will discuss the development of devices to synergistically optimize the benefit of leading drugs to treat cancer. Event Details Date: February 26th Time: 4pm Eastern (1pm Pacific) Force Family Office Event Description Healthcare is driven by innovation. New discoveries, technologies, applications, molecules, devices, and formulations are at the heart of an industry that never stands still. Which are the experts watching? One of those is Sigyn Therapy, a blood purification therapy with applications in infectious disease, oncology, dialysis and organ transplantation. Register now to join this Fireside Chat with Zacks Senior Healthcare Analyst, John Vandermosten, and Jim Joyce, CEO of Sigyn Therapeutics, for a discussion of innovations on the horizon that will be creating value in the healthcare sector. About Sigyn Therapeutics(TM) Sigyn Therapeutics is developing next-generation blood purification therapies to address cancer and life-threatening infectious disease disorders that are not treatable with drugs. The Company's lead product candidate, Sigyn Therapy(TM) has been demonstrated to reduce the presence of viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. Based on these capabilities, Sigyn Therapy(TM) is a candidate to treat life-threatening viral pathogens, antibiotic-resistant bacterial infections, endotoxemia, and sepsis, which is the leading cause of death in U.S. hospitals. The clinical protocol of first-in-human studies incorporates Sigyn Therapy with regularly scheduled dialysis treatments to address endotoxemia and concurrent inflammation, which are highly prevalent disorders that shorten the lives of end-stage renal disease (ESRD) patients. Extending the lives of those with ESRD could significantly impact dialysis industry revenues. The Company's oncology pipeline is comprised of ImmunePrep(TM), a platform to enhance the delivery of immunotherapeutic antibodies; ChemoPrep(TM) to improve the delivery of chemotherapeutic agents; and ChemoPure(TM) to reduce chemotherapy toxicity. If successfully advanced, the Company's therapies offer to provide strategic value to the dialysis and biopharmaceutical industry. CONTACTS: Sigyn Therapeutics, Inc. Johan Louw Senior Vice President of Strategic Programs 281.660.1815 [email protected] CEO, Inventor Cautionary Note Regarding Forward-Looking Statements This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. ('Sigyn') that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as 'may,' 'believe,' 'anticipate,' 'expect,' 'intend,' 'plan,' 'project,' 'will,' 'projections,' 'estimate,' 'potentially' or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption 'Risk Factors' in the Company's Annual Report on Form 10-K, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Yahoo
05-02-2025
- Business
- Yahoo
Sigyn Therapeutics to Present at Tomorrow's Small Cap Growth Virtual Investor Conference
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Sigyn Therapeutics, Inc. ('Sigyn' or the 'Company') (OTCQB: SIGY), a developer of next-generation blood purification technologies to treat cancer and life-threatening infectious disease disorders, today announced that Jim Joyce, the Company's CEO will present live at tomorrow's Small Cap Growth Virtual Investor Conference hosted by DATE: February 6th TIME: 3:30pm ETLINK: for 1x1 meetings: February 6th, 7th, 10th and 11th This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at About Sigyn Therapeutics™ Sigyn Therapeutics is developing next-generation blood purification therapies to address cancer and life-threatening infectious disease disorders that are not treatable with drugs. The Company's lead product candidate, Sigyn TherapyTM has been demonstrated to reduce the presence of viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. Based on these capabilities, Sigyn TherapyTM is a candidate to treat life-threatening viral pathogens, antibiotic-resistant bacterial infections, endotoxemia, and sepsis, which is the leading cause of death in U.S. hospitals. The clinical protocol of first-in-human studies incorporates Sigyn Therapy in series with regularly schedule dialysis treatments to address endotoxemia and concurrent inflammation which shorten the lives of end-stage renal disease (ESRD) patients. Extending the lives of individuals with ESRD could significantly impact dialysis industry revenues. The Company's oncology pipeline is comprised of ImmunePrepTM, a platform to enhance the delivery of immunotherapeutic antibodies; ChemoPrepTM to improve the delivery of chemotherapeutic agents; and ChemoPureTM to reduce chemotherapy toxicity. If successfully advanced, the Company's therapies offer to provide strategic value to the dialysis and biopharmaceutical industry. To learn more about Sigyn Therapeutics, visit: About Virtual Investor Conferences® Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS: Sigyn Therapeutics, Inc. Johan LouwSenior Vice President of Strategic Programs281.660.1815 jlouw@ Jim JoyceChairman, CEOEmail: jj@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ Cautionary Note Regarding Forward-Looking Statements This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. ('Sigyn') that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or in to access your portfolio
